ZA202104656B - Deuterated forms and derivatives of volinanserin - Google Patents
Deuterated forms and derivatives of volinanserinInfo
- Publication number
- ZA202104656B ZA202104656B ZA2021/04656A ZA202104656A ZA202104656B ZA 202104656 B ZA202104656 B ZA 202104656B ZA 2021/04656 A ZA2021/04656 A ZA 2021/04656A ZA 202104656 A ZA202104656 A ZA 202104656A ZA 202104656 B ZA202104656 B ZA 202104656B
- Authority
- ZA
- South Africa
- Prior art keywords
- volinanserin
- derivatives
- deuterated forms
- deuterated
- forms
- Prior art date
Links
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical class COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784056P | 2018-12-21 | 2018-12-21 | |
| PCT/US2019/067885 WO2020132461A1 (en) | 2018-12-21 | 2019-12-20 | Deuterated forms and derivatives of volinanserin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202104656B true ZA202104656B (en) | 2022-10-26 |
Family
ID=71101633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/04656A ZA202104656B (en) | 2018-12-21 | 2021-07-05 | Deuterated forms and derivatives of volinanserin |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220106272A1 (enExample) |
| EP (1) | EP3897507A4 (enExample) |
| JP (2) | JP7548906B2 (enExample) |
| KR (1) | KR20210124976A (enExample) |
| CN (1) | CN113747870B (enExample) |
| AU (1) | AU2019403391A1 (enExample) |
| BR (1) | BR112021012082A8 (enExample) |
| CA (1) | CA3124399A1 (enExample) |
| EA (1) | EA202191731A1 (enExample) |
| IL (1) | IL284201A (enExample) |
| MX (1) | MX2021007437A (enExample) |
| SG (1) | SG11202106692UA (enExample) |
| WO (1) | WO2020132461A1 (enExample) |
| ZA (1) | ZA202104656B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115057774A (zh) * | 2022-04-28 | 2022-09-16 | 北京绮一舟新材料技术有限公司 | 一种α-氘代羧酸衍生物类化合物及氘代药物的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2570961C (en) * | 2004-06-21 | 2015-09-01 | University Of Mississippi | Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities |
| US8198305B2 (en) * | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
| EP2185687A4 (en) * | 2007-08-06 | 2010-11-17 | Merck Sharp & Dohme | TREATMENT OF PSYCHOSES WITH A 5HT2A ANTAGONIST AND AN AGONIST OR AMPLIFIER OF A METABOTROPIC GLUTAMATE RECEPTOR |
| US8609673B2 (en) * | 2008-01-22 | 2013-12-17 | Concert Pharmaceuticals, Inc. | Vandetanib derivatives |
| WO2012039660A1 (en) * | 2010-09-20 | 2012-03-29 | A. Carlsson Research Ab | Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders |
| SG194625A1 (en) * | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
| LT3135656T (lt) * | 2011-06-20 | 2019-04-25 | H. Lundbeck A/S | Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui |
| WO2014145718A2 (en) * | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| WO2018023009A1 (en) * | 2016-07-29 | 2018-02-01 | Concert Pharmaceuticals, Inc. | Deuterated lurasidone |
-
2019
- 2019-12-20 MX MX2021007437A patent/MX2021007437A/es unknown
- 2019-12-20 EP EP19900289.0A patent/EP3897507A4/en active Pending
- 2019-12-20 KR KR1020217022981A patent/KR20210124976A/ko not_active Ceased
- 2019-12-20 EA EA202191731A patent/EA202191731A1/ru unknown
- 2019-12-20 CN CN201980092743.7A patent/CN113747870B/zh active Active
- 2019-12-20 CA CA3124399A patent/CA3124399A1/en active Pending
- 2019-12-20 US US17/416,011 patent/US20220106272A1/en not_active Abandoned
- 2019-12-20 JP JP2021535751A patent/JP7548906B2/ja active Active
- 2019-12-20 SG SG11202106692UA patent/SG11202106692UA/en unknown
- 2019-12-20 WO PCT/US2019/067885 patent/WO2020132461A1/en not_active Ceased
- 2019-12-20 AU AU2019403391A patent/AU2019403391A1/en not_active Abandoned
- 2019-12-20 BR BR112021012082A patent/BR112021012082A8/pt not_active Application Discontinuation
-
2021
- 2021-06-20 IL IL284201A patent/IL284201A/en unknown
- 2021-07-05 ZA ZA2021/04656A patent/ZA202104656B/en unknown
-
2024
- 2024-08-29 JP JP2024147359A patent/JP2024163142A/ja active Pending
- 2024-11-08 US US18/941,426 patent/US20250066302A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202106692UA (en) | 2021-07-29 |
| IL284201A (en) | 2021-08-31 |
| JP2024163142A (ja) | 2024-11-21 |
| JP7548906B2 (ja) | 2024-09-10 |
| KR20210124976A (ko) | 2021-10-15 |
| AU2019403391A1 (en) | 2021-08-05 |
| US20250066302A1 (en) | 2025-02-27 |
| BR112021012082A8 (pt) | 2023-03-21 |
| US20220106272A1 (en) | 2022-04-07 |
| WO2020132461A1 (en) | 2020-06-25 |
| EP3897507A1 (en) | 2021-10-27 |
| CA3124399A1 (en) | 2020-06-25 |
| BR112021012082A2 (pt) | 2021-08-31 |
| CN113747870A (zh) | 2021-12-03 |
| CN113747870B (zh) | 2025-08-01 |
| EP3897507A4 (en) | 2022-09-14 |
| JP2022515156A (ja) | 2022-02-17 |
| MX2021007437A (es) | 2021-09-08 |
| EA202191731A1 (ru) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3830085T1 (sl) | Devterirani derivati lanifibranorja | |
| IL274276A (en) | CASZ preparations and methods of use | |
| IL276687A (en) | Trialkyne coupling agents and methods of using them | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| IL274504A (en) | 2ACSS inhibitors and methods of their use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL276135A (en) | Preparations and methods of use | |
| IL276592A (en) | History of Subtirum | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| IL282527A (en) | 5-Azaindazole history and their use | |
| EP3749691A4 (en) | ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE | |
| IL276053A (en) | Therapeutic Gard and methods of its use | |
| GB2589398B (en) | Compounds and methods of use | |
| IL282526A (en) | 5-Azaindazole history and their use | |
| SG11202004693PA (en) | Synthesis of morin and morin derivatives | |
| IL274433A (en) | Fulvestrant formulations and methods of using them | |
| SG11202106692UA (en) | Deuterated forms and derivatives of volinanserin | |
| GB2574223B (en) | Adhesives and methods of forming adhesives | |
| IL283703A (en) | A polymorphic form of meisoindigo and a different formulation of meisoindigo | |
| IL282566A (en) | Synthesis of (s)-6-hydroxytryptophan and derivatives thereof | |
| HK40053042A (en) | Deuterated forms and derivatives of volinanserin | |
| GB201908573D0 (en) | Compounds and methods of use | |
| HK40034351A (en) | Angptl8-binding agents and methods of use thereof |